ALKINYLCHINAZOLIN-VERBINDUNGEN

European patent · EP4013749 · In force

Register entry

Publication number
EP4013749
Application number
EP20764505
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Aug 14, 2020
Published
Jun 22, 2022
Granted
Mar 11, 2026
Protection ends at the latest
Aug 13, 2040
Next annual fee due
Aug 31, 2027
IPC classes
C07D 401/06 (2006.01)
C07D 401/14 (2006.01)
C07D 403/06 (2006.01)
C07D 405/06 (2006.01)
C07D 405/14 (2006.01)
C07D 413/06 (2006.01)
C07D 413/14 (2006.01)
C07D 471/04 (2006.01)
C07D 471/08 (2006.01)
C07D 487/08 (2006.01)
C07D 491/10 (2006.01)
C07D 498/08 (2006.01)
A61K 31/5377 (2006.01)
A61K 31/517 (2006.01)
A61P 35/00 (2006.01)
Priority
US 201962887392 P 15.08.2019
US 202063065028 P 13.08.2020
PCT application
PCT/US2020/046425 14.08.2020
PCT publication
WO2021/030711 18.02.2021
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Sep 1, 2026

    Next annual fee due on

    Next annual fee due on
    31.08.2026 → 31.08.2027

    Published in Swissreg on 01.09.2026

  2. Mar 11, 2026

    Granted

    Specification status
    Non-published patent application → Granted patent
    Status of protective title
    Initiated → Active

    Published in Swissreg on 11.03.2026

Parties

Holder

Black Diamond Therapeutics, Inc.

245 First Street, 18th Floor, Cambridge, MA 02142, US

Inventor

LUCAS, Matthew C.

Lexington, Massachusetts 02421, US

PADILLA, Fernando

Arlington, Massachusetts 02474, US

FLOHR, Alexander

4051 Basel

ARISTA, Luca

4125 Riehen

BUCK, Elizabeth

Huntington, New York 11734, US

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.